QuantRx and Jant are exploring quantitative point of care technologies in areas of oncology, cardiovascular, and other emerging markets. The technologies are supported by strong IP positions as well as proof of concept and clinical data. QuantRx and Jant plan to launch several new products in 2008.
Jack Tawfik, managing director of Jant Pharmacal, stated, “We are excited about our collaboration with QuantRx. We are confident that our cooperation will result in the development and commercialization of unique and innovative technologies in the diagnostic and monitoring fields.”